Risks
4 risks
Risk Intelligence
Sustained margin improvement dependent on product mix
View Risks →Hester Biosciences Limited — Q3 FY26
Hester Biosciences reported a strong Q3 FY26 with standalone revenue growing 12% YoY and PAT surging 140% YoY, driven by favorable product mix and cost discipline.
bullish
medium
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Hester Biosciences reported a strong Q3 FY26 with standalone revenue growing 12% YoY and PAT surging 140% YoY, driven by favorable product mix and cost discipline. The poultry healthcare division led growth with 32% YoY revenue increase, supported by deeper market penetration and distribution expansion. The animal healthcare division declined 38% due to delayed government immunization programs, expected to recover in Q4. Key regulatory milestone achieved with H9N2 avian influenza vaccine license, opening domestic and export opportunities. The fill-finish facility was capitalized, doubling drug product capacity. Management aims to reduce tender dependence and strengthen commercial and export markets. Risk: sustained margin improvement depends on product mix management and institutional order timing.
हेस्टर बायोसाइंसेज ने वित्त वर्ष 2026 की तीसरी तिमाही में मजबूत प्रदर्शन किया। कंपनी की कमाई पिछले साल की तुलना में 12% बढ़ी, जबकि मुनाफा 140% उछल गया। इसकी वजह अच्छा उत्पाद मिश्रण और खर्च पर नियंत्रण था। पोल्ट्री हेल्थकेयर डिवीजन ने 32% राजस्व वृद्धि दर्ज की, क्योंकि बाजार में पहुंच और वितरण बढ़ाया गया। पशु स्वास्थ्य डिवीजन में 38% गिरावट आई, क्योंकि सरकारी टीकाकरण कार्यक्रम में देरी हुई, लेकिन चौथी तिमाही में इसमें सुधार की उम्मीद है। कंपनी को H9N2 बर्ड फ्लू वैक्सीन का लाइसेंस मिला, जिससे देश और विदेश में बिक्री के नए रास्ते खुलेंगे। नई फैक्ट्री से दवा बनाने की क्षमता दोगुनी हो गई। प्रबंधन सरकारी ऑर्डर पर निर्भरता कम करके कमर्शियल और निर्यात बाजार पर ध्यान देगा। जोखिम: मुनाफा बनाए रखने के लिए उत्पाद मिश्रण और संस्थागत ऑर्डर के समय पर नियंत्रण जरूरी है।
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Poultry Healthcare Revenue Growth (Q3)
32%
+32% YoY
Poultry division grew 32% in Q3 FY26, driven by deeper market penetration and distribution coverage.
PAT Growth (Q3 Standalone)
140%
+140% YoY
Standalone PAT increased 140% YoY in Q3, reflecting favorable product mix and cost discipline.
Animal Healthcare Revenue Decline (Q3)
-38%
-38% YoY
Animal healthcare division declined 38% due to delays in government immunization programs.
Africa Revenue (9 Months)
₹27.5 Cr
N/A
Africa operations generated ₹27.5 crore revenue in 9 months, with long-term institutional demand.
Fast read
Guidance and risk preview
Government immunization programs for PPR and goatpox (LSD) are expected to commence from February 2026, improving animal health division momentum i...
Management acknowledged that quarterly margins are influenced by product mix and cannot be guaranteed, though year-on-year improvement is targeted.
View Risks →